Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNAF), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics Corp. (MDNAF) is a clinical-stage immunotherapy company whose news flow is closely tied to the progress of its Superkine pipeline. Company updates consistently highlight advances in MDNA11, a long-acting IL-2 Superkine in the Phase 1/2 ABILITY-1 trial for advanced solid tumors, as well as developments in MDNA113, a tumor-anchored and conditionally activated PD-1 x IL-2 bifunctional Superkine, and bizaxofusp (MDNA55), an IL-4 Empowered Superkine for recurrent glioblastoma.
On this page, readers can follow MDNAF news related to clinical data readouts, new trial announcements and corporate milestones. Recent releases describe updated MDNA11 results in monotherapy and in combination with pembrolizumab, including activity in checkpoint inhibitor-resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H tumors, as well as plans to complete enrollment in ABILITY-1 and prepare for potential registrational studies. News also covers the NEO-CYT neoadjuvant trial in high-risk, surgically resectable Stage III melanoma, sponsored by Fondazione Melanoma Onlus, which will evaluate MDNA11 in combination with nivolumab with or without ipilimumab.
Investors and clinicians can also track preclinical and non-human primate updates for MDNA113, including safety and pharmacodynamic findings that Medicenna reports as supporting its advancement toward first-in-human trials. Additional news items address partnering efforts and data presentations for bizaxofusp in recurrent glioblastoma, patent issuances protecting IL-2 and IL-4 Superkine assets, and participation in scientific and investor conferences.
By reviewing the MDNAF news feed, users can see how Medicenna communicates new clinical results, outlines expected milestones, and provides context on the scientific rationale behind its Superkine programs, while also including standard cautions about the risks and uncertainties inherent in drug development.
Medicenna (OTCQX: MDNAF) said President and CEO Dr. Fahar Merchant will present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21, 2026 at 3:00 p.m. ET.
The company will provide a corporate update and share latest MDNA113 preclinical data from AACR 2026. A live webcast and a replay (available for 90 days) are accessible via the company webcast link and the Investor Relations site.
Medicenna (TSX: MDNA, OTCQX: MDNAF) named Dr. Nageatte Ibrahim as Chief Medical Officer effective April 9, 2026. Dr. Ibrahim will serve in a fractional capacity and brings >20 years of oncology drug‑development experience, including roles at Merck, GSK, Innovent, and academic appointments at Harvard and Penn.
Her experience includes leadership on pembrolizumab programs and oversight of global registration studies, supporting Medicenna’s IL‑2 superagonist and anti‑PD1‑IL‑2 bifunctional programs.
Medicenna (OTCQX: MDNAF) will present updated preclinical data for MDNA113, a masked, tumor‑anchored anti‑PD‑1‑IL‑2 bifunctional Superkine, at AACR Annual Meeting 2026 on April 21 (Poster Section 9, Board 13).
The program is advancing toward an IND submission in H2 2026 and the poster highlights in vivo tumor selectivity, localization, potency and non‑human primate immunodynamic and safety data supporting a differentiated tolerability profile.
Medicenna (OTCQX: MDNAF, TSX: MDNA) announced participation in multiple industry conferences between Feb 19 and Mar 25, 2026 to present clinical program updates and meet investors.
Key events: Feb 19 Boston (Glioblastoma Summit) — presentation by Dr. Fahar Merchant on bizaxofusp; Mar 2-3 Miami (BIO Investment); Mar 22-24 Dana Point (ROTH) webcast available; Mar 23-25 Lisbon (BIO-Europe Spring).
Medicenna (OTCQX: MDNAF) reported Q3 fiscal 2026 results and a corporate update on Feb 13, 2026. Key clinical wins include MDNA11 ORR 36% (mono) and 43% (combo) in expansion cohorts and bizaxofusp mOS 13.6 months in IDHWT high-dose rGBM. Cash was $10.6M, providing runway into Q3 2026.
MDNA113 advanced through IND-enabling studies with favorable NHP safety at 30 mg/kg; multiple clinical readouts and an IND filing are planned in H2 2026.
Medicenna (TSX: MDNA, OTCQB: MDNAF) announced board changes effective Feb 12, 2026: Richard Sutin and Angelos Georgakis were appointed to the board, following the retirement of Karen Dawes, who served since 2019 and chaired the Compensation Committee. The company highlighted their capital markets and biotech advisory experience.
The CEO said the new directors will support strategic growth and that Dawes will continue as a consultant.
Medicenna (OTCQX: MDNAF) provided a 2026 outlook and program updates focused on MDNA11, MDNA113 and bizaxofusp. ABILITY-1 has enrolled >110 safety-evaluable patients (102 efficacy-evaluable) across 29 cancer types; biologically effective dose range was set at 60–120 µg/kg with no dose-limiting toxicities. Key efficacy: monotherapy expansion cohorts (n=21) showed 50% ORR in 2L/3L patients and 42% ORR post-ICI failure; overall monotherapy (n=55) ORR was 19% (2L/3L) and 24% (post-ICI). MDNA113 NHP data tolerable to 30 mg/kg; IND planned H2 2026. Cash runway into Q3 2026.
Medicenna (OTCQX: MDNAF) presented updated Phase 1/2 ABILITY-1 data for MDNA11 at ESMO-IO Congress on Dec 10, 2025. Key findings at the Biological Effective Dose Range (60–120 µg/kg Q2W/Q3W) include monotherapy ORR of 42% and DCR of 83% in patients treated after progression on immune checkpoint inhibitors, ORR of 38% in checkpoint-resistant melanoma, and ORR of 22% in MSI-H tumors. Combination with KEYTRUDA showed ORR/DCR of 50%/75% in MSS endometrial cancer and 25%/88% in TMB-H tumors. Median OS was longer in patients achieving disease control (monotherapy mOS 120.2 vs 28.6 weeks; combination mOS not reached vs 26 weeks). Safety was manageable with >90% Grade 1–2 TRAEs and no DLTs up to 120 µg/kg.
Medicenna (OTCQX: MDNAF; TSX: MDNA) will host a live webinar on December 10, 2025 at 08:30 AM ET to discuss updated clinical data from the ABILITY-1 Phase 1/2 study evaluating MDNA11 as a monotherapy and in combination with pembrolizumab. The event features presentations by company management and the presenting Principal Investigator, followed by commentary from key opinion leaders and live Q&A.
Presenters include Dr. Fahar Merchant (President and CEO), Dr. Arash Yavari (Director of Clinical Strategy) and Dr. André Mansinho (presenting Principal Investigator). Registration is required and a replay will be available on Medicenna’s website after the event.
Medicenna (OTCQX: MDNAF, TSX: MDNA) reported Q2 fiscal 2026 results and a corporate update on Nov 13, 2025. Key clinical milestones include an MDNA11 data presentation at ESMO IO Congress on Dec 10, 2025 and a randomized neoadjuvant NEO-CYT trial in Italy (up to 12 centres) testing MDNA11 with nivolumab ± ipilimumab. MDNA113 is in non-human primate studies with IND-enabling work planned H1 2026 and a first-in-human trial targeted H2 2026. Six patents were issued or allowed across US, Japan, Canada and Australia. Cash was $15.7M, providing runway into at least mid-2026.